Literature DB >> 29031928

The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.

Yongrong Zhang1, Zhiyong Yang1, Si Gao1, Therwa Hamza1, Harris G Yfantis2, Michael Lipsky3, Hanping Feng4.   

Abstract

Most pathogenic Clostridium difficile produce two major exotoxins TcdA and TcdB, in the absence of which the bacterium is non-pathogenic. While it is important to investigate the role of each toxin in the pathogenesis of C. difficile infection (CDI) using isogenic strains, it is impossible to precisely control the expression levels of individual toxins and exclude bacterial factors that may contribute to the toxins' effects during infection. In this study, we utilized an acute intestinal disease model by injecting purified toxins directly into mouse cecum after a midline laparotomy. We evaluated the physical condition of mice by clinical score and survival, and the intestinal tissue damage and inflammation by histology. Depending on the dose of the toxins, mice developed mild to severe colitis, experienced diarrhea or rapidly died. We found that both purified TcdA and TcdB were able to induce clinical disease, intestinal inflammation, and tissue damage that resembled CDI. TcdA was significantly faster in inducing intestinal inflammation and tissue damage, and was approximately five times more potent than TcdB in terms of inducing severe gut disease and death outcomes in mice. Moreover, we found that the two toxins had significant synergistic effects on disease induction. Comparison of the in vivo toxicity of TcdB from clinical strains revealed that TcdB from an epidemic RT 027 strain was more toxic than the others. Our study thus demonstrates that both TcdA and TcdB, independent of other factors from C. difficile bacterium, are able to cause disease that resembles CDI and highlights the importance of targeting both toxins for vaccines and therapeutics against the disease.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Cecum; Clostridium difficile; Pathogenesis; Toxin A; Toxin B

Mesh:

Substances:

Year:  2017        PMID: 29031928      PMCID: PMC5792825          DOI: 10.1016/j.anaerobe.2017.10.006

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  43 in total

1.  Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.

Authors:  E Chaves-Olarte; M Weidmann; C Eichel-Streiber; M Thelestam
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

3.  Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis.

Authors:  Zhiyong Yang; Yongrong Zhang; Tuxiong Huang; Hanping Feng
Journal:  Gut Microbes       Date:  2015-06-19

4.  Human alpha-defensins inhibit Clostridium difficile toxin B.

Authors:  Torsten Giesemann; Gregor Guttenberg; Klaus Aktories
Journal:  Gastroenterology       Date:  2008-03-10       Impact factor: 22.682

5.  The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins.

Authors:  I Just; M Wilm; J Selzer; G Rex; C von Eichel-Streiber; M Mann; K Aktories
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

6.  Toxin A of Clostridium difficile: production, purification and effect in mouse intestine.

Authors:  I Lönnroth; S Lange
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1983-12

7.  Identification of toxemia in patients with Clostridium difficile infection.

Authors:  Hua Yu; Kevin Chen; Jianguo Wu; Zhiyong Yang; Lianfa Shi; Lydia L Barlow; David M Aronoff; Kevin W Garey; Tor C Savidge; Erik C von Rosenvinge; Ciaran P Kelly; Hanping Feng
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

8.  Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.

Authors:  Glen P Carter; Anjana Chakravorty; Tu Anh Pham Nguyen; Steven Mileto; Fernanda Schreiber; Lucy Li; Pauline Howarth; Simon Clare; Bliss Cunningham; Susan P Sambol; Adam Cheknis; Iris Figueroa; Stuart Johnson; Dale Gerding; Julian I Rood; Gordon Dougan; Trevor D Lawley; Dena Lyras
Journal:  MBio       Date:  2015-06-02       Impact factor: 7.867

9.  Prevalence and pathogenicity of binary toxin-positive Clostridium difficile strains that do not produce toxins A and B.

Authors:  C Eckert; A Emirian; A Le Monnier; L Cathala; H De Montclos; J Goret; P Berger; A Petit; A De Chevigny; H Jean-Pierre; B Nebbad; S Camiade; R Meckenstock; V Lalande; H Marchandin; F Barbut
Journal:  New Microbes New Infect       Date:  2014-11-08

10.  A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity.

Authors:  Yongrong Zhang; Lianfa Shi; Shan Li; Zhiyong Yang; Clive Standley; Zhong Yang; Ronghua ZhuGe; Tor Savidge; Xiaoning Wang; Hanping Feng
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more
  4 in total

1.  Establishment of a gnotobiotic pig model of Clostridioides difficile infection and disease.

Authors:  Charlotte Nyblade; Viviana Parreno; Peng Zhou; Casey Hensley; Vanessa Oakes; Hassan M Mahsoub; Kelsey Kiley; Maggie Frazier; Annie Frazier; Yongrong Zhang; Hanping Feng; Lijuan Yuan
Journal:  Gut Pathog       Date:  2022-06-06       Impact factor: 5.324

2.  Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B.

Authors:  Peng Chen; Liang Tao; Tianyu Wang; Jie Zhang; Aina He; Kwok-Ho Lam; Zheng Liu; Xi He; Kay Perry; Min Dong; Rongsheng Jin
Journal:  Science       Date:  2018-05-11       Impact factor: 47.728

3.  Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.

Authors:  Rudo Simeon; Mengqiu Jiang; Ana M Chamoun-Emanuelli; Hua Yu; Yongrong Zhang; Ran Meng; Zeyu Peng; Joanita Jakana; Junjie Zhang; Hanping Feng; Zhilei Chen
Journal:  PLoS Biol       Date:  2019-06-24       Impact factor: 8.029

4.  Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection.

Authors:  Peng Chen; Ji Zeng; Zheng Liu; Hatim Thaker; Siyu Wang; Songhai Tian; Jie Zhang; Liang Tao; Craig B Gutierrez; Li Xing; Ralf Gerhard; Lan Huang; Min Dong; Rongsheng Jin
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.